22157.jpg
Pancreatic Cancer Drugs Global Market Report 2024
07 mars 2024 04h09 HE | Research and Markets
Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The pancreatic cancer drugs market size...
Global Pancreatic Cancer Drugs Market
$3.4+ Billion Worldwide Pancreatic Cancer Drugs Industry to 2031 - Identify Growth Segments for Investment
14 avr. 2022 06h38 HE | Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Drugs Global Market Report 2022, Type, End User, Drugs" report has been added to ResearchAndMarkets.com's offering. This report...
22157.jpg
World Pancreatic Cancer Clinical Landscape Spotlight 2021-2031
11 juin 2021 05h33 HE | Research and Markets
Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Pancreatic Cancer" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Pancreatic...
22157.jpg
Global Pancreatic Cancer Opportunity Analysis and Forecasts Report 2020: Market Expected to Grow at 11.5% CAGR to $5.4B During 2019-2029
06 janv. 2021 11h03 HE | Research and Markets
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. Pancreatic cancer is...
MateonLogo.jpg
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
23 juin 2020 07h00 HE | Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
PMCB YT .png
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
14 janv. 2020 09h00 HE | PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer
30 mai 2019 19h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
PMCB YT .png
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
23 janv. 2019 09h25 HE | PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...
PharmaCyte Closing i
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer
21 mai 2018 09h20 HE | PharmaCyte Biotech
NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application...
PharmaCyte Biotech M
PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial
01 déc. 2016 09h00 HE | PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - December 01, 2016) - PharmaCyte Biotech (OTCQB: PMCB) is now one step closer to enrolling patients in a pivotal clinic trial in advanced, inoperable pancreatic cancer...